ALL Metrics
-
Views
-
Downloads
Get PDF
Get XML
Cite
Export
Track
Clinical Practice Article
Revised

Use of Remdesivir in the treatment of Coronavirus Disease 2019 (COVID-19) infection among Sudanese patients: a case series

[version 2; peer review: 2 approved]
PUBLISHED 10 Mar 2022
Author details Author details
OPEN PEER REVIEW
REVIEWER STATUS

This article is included in the Coronavirus (COVID-19) collection.

Abstract

Introduction: The coronavirus disease 2019 (COVID-19) pandemic is affecting populations worldwide. Remdesivir is an anti-retroviral agent, with a broad spectrum of usage. Remdesivir usage against COVID-19 had been studied both in vitro and in vivo but is still considered a new treatment for COVID-19 and is not available in all countries. The aim of our study was to report several cases of the use of Remdesivir in Sudanese patients and report the adverse events related to the course of treatment.
Methods: A case series study was conducted in Imperial Hospital, Khartoum, Sudan reporting two cases who received Remdesivir for treating COVID-19 besides other treatments such as steroids and supportive therapy in December 2020. Cases were males aged over 65 years.
Cases presentation: Both patients were severe cases of COVID-19 admitted to the intensive care unit (ICU), who received Remdesivir for treating COVID-19 infection. Several side effects were reported: the first case had increased liver enzymes and then unexpectedly died from severe resistant hypotension; and hypoalbuminemia was noticed in the second case.
Conclusions: Remdesivir use among patients in Sudan must be studied extensively in order to determine the unexpected fatal event and assess the association of this event to Remdesivir use, as well as to report the frequency of the side effects.

Keywords

COVID-19, treatment, liver enzymes, Remdesivir, hypotension, Imperial Hospital, Sudan, Sudanese patients.

Revised Amendments from Version 1

In this updated version, more details about the ethical approval review committee were added, such as the date and reference of the ethical approval. Furthermore, details about the figure describing the computed tomography (CT) findings were included, Nevertheless, the source of information about COVID-19 treatment was detailed in order to clarify the standard protocol used for the patients. Finally, a complete revision of all the writing structures was done.

See the authors' detailed response to the review by Bashir Alsiddig Yousef
See the authors' detailed response to the review by Andri Frediansyah

Abbreviations

CPAP: Continuous Positive Airway Pressure

CT: Computed Tomography

DM: Diabetes Mellitus

FFP: Fresh Frozen Plasma

GCS: Glasgow Coma Scale

ICU: Intensive Care Unit

IgG: Immunoglobulin G

IgM: Immunoglobulin M

I.V.: Intravenously

MOH: Ministry of health

PCR: Polymerase Chain Reaction

RNA: Ribonucleic Acid

RT-PCR: Reverse Transcription Polymerase Chain Reaction

SARS-COV-2: Severe Acute Respiratory Syndrome

SPO2: Oxygen Saturation

Introduction

The coronavirus disease 2019 (COVID-19) pandemic is affecting people worldwide with all populations susceptible to getting infected; especially health care personnel and elderly populations.1 Concomitant comorbid conditions, such as diabetes mellitus (DM), are related to increased severity of COVID-19 symptoms.1,2 Remdesivir is an anti-retroviral agent, with a broad spectrum of activity. It is a prodrug, which was first developed to be used for the treatment of Ebola.3 Recently, it was proposed to treat COVID-19 infection.4,5 The use of Remdesivir against COVID-19 had been studied both in vitro and in vivo, but still considered new for COVID-19 treatment and not available in all countries.6,7 Although some Remdesivir trials have not had enough power,8 one large scale clinical trial has been done, in which, there was no statistically significant difference in the improvement time with the use of Remdesivir (hazard ratio 1.23 [95% confidence interval (CI) 0.87–1.75]. Further, the course of Remdesivir was stopped early due to the side effects noted in 12% of the patients which included increased alanine and other side effects.9 The aim of our study was to report the use of Remdesivir among two cases in Sudan and report the adverse events related to the course of treatment.

Methods

A case series study design was implemented involving two Sudanese patients. Cases are described in detail below. The data were collected retrospectively from the medical records. Confidentiality of participants was assured through the use of an anonymous research tool that had no identifiers to the involved patients and documented the medical data through codes. This data collection sheet was developed by the researchers and validated by a specialist in research methodology with a PhD. Epi-info-7 was used.

Ethical approval and participant consent

Approval was firstly obtained from the Medical administration of Imperial Hospital. The study proposal was then submitted to the Administration of Innovation and Scientific Research at the State Ministry of Health (MOH), Khartoum, Sudan. Expedited review was conducted by the Institutional Review Board (IRB) of the MOH and approval was granted on 17-Jan-2021 case number: 44/A. Another copy of the proposal was submitted to the Administration of Private Medical Facilities.

Since the study was conducted using the archived medical records of the patients after death or discharge, informed consent was obtained from surrogate decision makers by contacting them through their registered phone numbers. In our study, the wives gave the approval after consulting the family. The objectives of the study and what data would be collected from the patients' medical records was explained in full. The collected data were used strictly for the purpose of the study objectives.

Case 1 presentation

A 78 years old male presented to the emergency isolation room at Imperial hospital, Khartoum, Sudan on 8 December 2020. The patient was tested for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and antibodies on 4 December 2020 (brand of tests unknown) and the results were received on 5 December. SARS-CoV-2 RNA by polymerase chain reaction (PCR) was detected, while the SARS-CoV-2 antibody test was negative. The patient had been complaining of shortness of breath for 3 days. His comorbidities were diabetes mellitus (DM) for which he was on insulin treatment, and a history of colon cancer for which he had an operation two 2 years previously and he was on oral chemotherapy. The patient had no other co-morbid conditions. A confirmatory test by using reverse transcription polymerase chain reaction (RT-PCR) was done on 10 December confirming the infection (brand of the test unknown). The medications in Table 1 were given to the patient from day 1 and planned for 10 days, besides 1.5 litres of fluids per day. The patient was admitted to the isolation ICU on the same day of hospital arrival.

Table 1. COVID-19 treatment medications administered to the patients.

Medications
Remdesivir 200 mg I.V. LD, 100 mg I.V. O.D.
Meropenem 1 gm I.V. B.D.
Enoxaparin 40mg S.C. B.D.
Dexamethasone 6 mg O.D. I.V.
Paracetamol 1gm I.V. on need
Pantoprazole 40 mg I.V. O.D.
Vitamin C 1000 mg O.D.
Zinc sulphate 15 mg O.D.
Azithromycin 500 mg O.D.
Salbutamol nebulized solution 6 Hourly
Ipratropium nebulized solution 6 Hourly
Pulmicort 0.5 gm nebulized solution 6 Hourly

Remdesivir was started on day 1, 8 December 2020. A loading dose of 200 mg was given in 250 mL of normal saline followed by a maintenance dose of 100 mg intravenously (I.V.) in 250 mL of normal saline once daily, planned for 10 days. On admission, the patient's oxygen saturation (SPO2) was 92% and continuous positive airway pressure (CPAP) was applied. Table 2 illustrates the daily vital signs of the patient.

Table 2. Daily vital signs of the patient (Case 1).

Vital
signs
Day 1
8/12/2020
Day2
9/12l2020
Day 3
10/12/2020
Day 4
11/12/2020
Day 5
12/12/2020
Day 6
13/12/2020
SPO292%94%95%94%90%83%, 80%
RR303533303234
HR (taken twice/day day 1-3)100 bpm
109 bpm
128
115 bmp
122
130 bpm
130 bpm132 bpm125 bpm
B.P.130/70
140/80
139/87
133/85
149/92
168/100
170/83155/8399/56
Undetectable
84/40
GCS15/1515/1513/1510/1510/153/15
RBG (taken twice/day)233 mg/dl
402 mg/dl
343
230
300
370
350
310
369
368
268
280
Temp. (degrees Celsius)37.336.036.4

Laboratory examinations were done daily starting from day 3, 10 December 2020. The results are presented in Table 3.

Table 3. Results of laboratory examinations of the patient (Case 1).

Laboratory testsDay 3Day 5Laboratory testsDay 3Day 5
Blood Urea121 mg/dlpH7.347
Serum creatinine1.2 mg/dlSO2%97.50%
Na+ (Sodium)153 mmol/L165.2 mmol/LHCO327meq/L
K+ (Potassium)5.3 mmol/L4.66 mmol/LHct49.50%
D-dimer5mcg/mlCl114.5 mmol/L
CRP215 mg/LTotal protein7.5 g/dL7.6 g/dL
TWBCs17.7*10^9/LSerum albumin2.4 g/dL2.6 g/dL
RBCs5.7*10^9/LALP97 U/L111 U/L
Neutrophils88*10^9/LALT (GPT)288 I.U/L142 I.U/L
Lymphocytes7*10^9/LAST (GOT)431 I.U/L70 I.U/L
PLts351*10^9/LProthrombin time65 Sec24 Sec
PCO250.6 mmHgINR>101.8
PO2105.4 mmHgAPTT49 Sec

Chest computed tomography was done for the patient on the first day of hospital arrival, 8 December, shown in Figure 1.

b26a1ced-6952-4fa1-94e8-22c39f4b4a54_figure1.gif

Figure 1. Chest computed tomography of case 1 on hospital arrival.

In the computed tomography image of case-1 as presented in Figure 1, ground-glass appearance was prevalent in both lungs indicating pneumonia related to COVID-19 infection. On day 3, the patient started deteriorating as the GCS was reducing. Nasogastric feeding was started and I.V. fluids were increased to 3 litres per day alongside the same plan. On day 6, severe hypotension had occurred in the patient, to an extent that blood pressure was undetectable on any monitor or manual devices. Hypotension was resistant to fluids and vasopressors which eventually led to the death of the patient. The patient was deceased on day 6, 13 December 2020, as a result of severe refractory hypotension.

Case 2 presentation

A 75 years old male presented to the Emergency Isolation room at Imperial hospital on 18 December 2020, with generalized fatigue and fever for 1 week, and hemiparesis. Co-morbid conditions of the patient were a pacemaker device and benign prostate enlargement (BPH) condition, which was operated on five years previously. Oxygen saturation with CPAP mask was 87%. The patient was diagnosed with COVID-19, pneumonia and sepsis which were confirmed by PCR and CT-chest. An incidence of haemorrhagic stroke was confirmed through brain imaging. The patient was admitted to the Isolation ICU immediately, with reduced GCS (9/15). Respiratory support was initiated with physiotherapy and prone positioning for 16 hours per day. The patient was administered 3 units of fresh frozen plasma (FFP) once, platelet concentrate 50 U/Kg once and vitamin K 10 mg I.V. once. The patient developed hypernatremia (Serum Na+ 153), International normalized ratio (2.8). Remdesivir was initiated on day 1 of admission (18 December 2020), by the dose detailed in Table 1, and stopped on day 5, 23 December 2020. Hypoalbuminemia was noticed on 24 December (2.2 g/dl), for which albumin 20% infusion was given twice daily for 4 days, the serum albumin level results after treatment were not recorded. On 27 December, the 10th day of hospital admission, the patient was transferred to a different healthcare facility, based on the request of the surrogate decision maker of the patient, and we had no follow up information after the discharge from Imperial Hospital. The medications in Table 1, were given exactly to the patient during the hospital stay, same as for Case 1.

Discussion

Our patients were aged 75 and 78 years, similar ages to other published studies9,10 being above 65 years. Both study cases were male, as COVID-19 infection is more prevalent in males.1012 COVID-19 treatment protocol given was consistent with the national protocol released by the Federal Ministry Of Health, Sudan (http://sho.gov.sd/corona/). In our study, case 1 was diabetic, which is known to be associated with increased COVID-19 severity of infection.2 This comorbidity was reported for 25% and 16% of patients who received Remdesivir.9,10 Remdesivir is considered a viable treatment option in severe COVID-19 infections.13,14 Remdesivir doses administered for our patients were a 200 mg intravenously loading dose followed by 100 mg daily dose, which is the recommended dosage.9,15 Both cases had received antibiotics and steroids along with Remdesivir, which is in line with.9

Hypoalbuminemia has been reported in patients taking Remdesivir,9 as in case 2 of our study. But case 1 had hypoalbminemia on presentation. The case 1 patient had 6 treatment days with Remdesivir, with no improvement, in contrast to published trials in which Remdesivir treatment course of 5 days has shown significant improvements.16,17 Our second case patient received Remdesivir after 4 days of presentation of COVID-19 symptoms, which is consistent with published literature reporting that the efficacy of Remdesivir is higher in patients who receive it within 10 days of symptom presentation.18 While another study concluded that delayed treatment initiation with Remdesivir was beneficial as well.19

Liver enzymes abnormalities have also been reported among patients who received Remdesivir.4,10,20 For such cases, treatment course should be stopped.14 In our first case, liver enzymes were extremely elevated since day 3 of treatment (Table 3), but Remdesivir course had not been discontinued. One of our cases was deceased and that was expected, as per a case series study in US, in which 50% of patients with severe COVID-19 infection on Remdesivir were deceased.21 Also, in a clinical study only 3% of patients on Remdesivir had clinical improvement on day 7.9 In another study, compassionate use of Remdesivir resulted in improvements in 69% of patients.10 The cause of death was severe resistant hypotension, which has been reported as a serious event in Remdesivir use.10,20

The limitations of our study were the observational nature of case series that cannot establish direct cause-effect relationships. Also, the data were collected retrospectively from the medical records of the patients which had some missing medical results. Furthermore, computed tomography image for case-2 was unavailable.

Conclusions and recommendations

Both patients were severe cases of COVID-19 admitted to the ICU. Unexpectedly, severe resistant hypotension was the cause of death of one of the patients. Increased liver enzymes was noticed in one case (case 1), as well as hypoalbuminemia (case 2). Wider studies regarding Remdesivir use among patients in Sudan must be conducted extensively in order to study this unexpected fatal event and assess the association of this event to Remdesivir use, as well as, to report the frequency of the side effects.

Consent

Written informed consent for publication of their clinical details and images was obtained from the surrogate decision makers of the patients. The surrogate decision makers gave written informed consent before data was collected and this was confirmed again after the manuscript was completed.

Data availability

All data underlying the results are available as part of the article and no additional source data are required.

Comments on this article Comments (0)

Version 2
VERSION 2 PUBLISHED 29 Jun 2021
Comment
Author details Author details
Competing interests
Grant information
Copyright
Download
 
Export To
metrics
Views Downloads
F1000Research - -
PubMed Central
Data from PMC are received and updated monthly.
- -
Citations
CITE
how to cite this article
Yousif M, Abd El-Raheem GOH and Mohamed D. Use of Remdesivir in the treatment of Coronavirus Disease 2019 (COVID-19) infection among Sudanese patients: a case series [version 2; peer review: 2 approved]. F1000Research 2022, 10:512 (https://doi.org/10.12688/f1000research.51375.2)
NOTE: If applicable, it is important to ensure the information in square brackets after the title is included in all citations of this article.
track
receive updates on this article
Track an article to receive email alerts on any updates to this article.

Open Peer Review

Current Reviewer Status: ?
Key to Reviewer Statuses VIEW
ApprovedThe paper is scientifically sound in its current form and only minor, if any, improvements are suggested
Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit.
Not approvedFundamental flaws in the paper seriously undermine the findings and conclusions
Version 2
VERSION 2
PUBLISHED 10 Mar 2022
Revised
Views
6
Cite
Reviewer Report 22 Mar 2022
Andri Frediansyah, National Research and Innovation Agency (BRIN), Jakarta, Indonesia;  Indonesian Institute of Sciences (LIPI), Wonosari, Indonesia 
Approved
VIEWS 6
I am satisfied with the ... Continue reading
CITE
CITE
HOW TO CITE THIS REPORT
Frediansyah A. Reviewer Report For: Use of Remdesivir in the treatment of Coronavirus Disease 2019 (COVID-19) infection among Sudanese patients: a case series [version 2; peer review: 2 approved]. F1000Research 2022, 10:512 (https://doi.org/10.5256/f1000research.122150.r126872)
NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article.
Version 1
VERSION 1
PUBLISHED 29 Jun 2021
Views
10
Cite
Reviewer Report 23 Feb 2022
Andri Frediansyah, National Research and Innovation Agency (BRIN), Jakarta, Indonesia;  Indonesian Institute of Sciences (LIPI), Wonosari, Indonesia 
Approved with Reservations
VIEWS 10
Two COVID-19 cases (aged 74 and 75 years) were treated at Sudan's Imperial Hospital, and the authors conducted a case series study to assess remdesivir's efficacy. According to two case series, adverse events such as elevated liver enzymes and hypoalbuminemia ... Continue reading
CITE
CITE
HOW TO CITE THIS REPORT
Frediansyah A. Reviewer Report For: Use of Remdesivir in the treatment of Coronavirus Disease 2019 (COVID-19) infection among Sudanese patients: a case series [version 2; peer review: 2 approved]. F1000Research 2022, 10:512 (https://doi.org/10.5256/f1000research.54536.r122200)
NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article.
  • Author Response 08 Mar 2022
    Ghada Abd El-Raheem, Pharmacy, Imperial Hospital, Military Hospital, Soba University Hospital, Khartoum, 11114, Sudan
    08 Mar 2022
    Author Response
    Dear Reviewer,
    Thank you for your valuable comments. I have fulfilled them all.
    Thank you again for your precious time.
    Competing Interests: No competing interest
COMMENTS ON THIS REPORT
  • Author Response 08 Mar 2022
    Ghada Abd El-Raheem, Pharmacy, Imperial Hospital, Military Hospital, Soba University Hospital, Khartoum, 11114, Sudan
    08 Mar 2022
    Author Response
    Dear Reviewer,
    Thank you for your valuable comments. I have fulfilled them all.
    Thank you again for your precious time.
    Competing Interests: No competing interest
Views
8
Cite
Reviewer Report 03 Dec 2021
Bashir Alsiddig Yousef, Department of Pharmacology, Faculty of Pharmacy, University of Khartoum, Khartoum, Sudan 
Approved
VIEWS 8
Authors performed a case series study to assess the use of remdesivir among two COVID-19 cases in Imperial Hospital, Khartoum, Sudan. Generally, the study is interesting and well presented. However, some points which should be reconsidered in this study: ... Continue reading
CITE
CITE
HOW TO CITE THIS REPORT
Alsiddig Yousef B. Reviewer Report For: Use of Remdesivir in the treatment of Coronavirus Disease 2019 (COVID-19) infection among Sudanese patients: a case series [version 2; peer review: 2 approved]. F1000Research 2022, 10:512 (https://doi.org/10.5256/f1000research.54536.r99911)
NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article.
  • Author Response 08 Mar 2022
    Ghada Abd El-Raheem, Pharmacy, Imperial Hospital, Military Hospital, Soba University Hospital, Khartoum, 11114, Sudan
    08 Mar 2022
    Author Response
    Dear Reviewer,
    Thank you for your valuable comments. I have fulfilled them all in the updated version.
    Thank you again for your precious time.
    Competing Interests: No competing interest.
COMMENTS ON THIS REPORT
  • Author Response 08 Mar 2022
    Ghada Abd El-Raheem, Pharmacy, Imperial Hospital, Military Hospital, Soba University Hospital, Khartoum, 11114, Sudan
    08 Mar 2022
    Author Response
    Dear Reviewer,
    Thank you for your valuable comments. I have fulfilled them all in the updated version.
    Thank you again for your precious time.
    Competing Interests: No competing interest.

Comments on this article Comments (0)

Version 2
VERSION 2 PUBLISHED 29 Jun 2021
Comment
Alongside their report, reviewers assign a status to the article:
Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested
Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit.
Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions
Sign In
If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.

The email address should be the one you originally registered with F1000.

Email address not valid, please try again

You registered with F1000 via Google, so we cannot reset your password.

To sign in, please click here.

If you still need help with your Google account password, please click here.

You registered with F1000 via Facebook, so we cannot reset your password.

To sign in, please click here.

If you still need help with your Facebook account password, please click here.

Code not correct, please try again
Email us for further assistance.
Server error, please try again.